|
15 Feb 2022 |
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
|
|
15 Feb 2022 |
Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
|
|
12 Feb 2022 |
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
|
|
11 Feb 2022 |
Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
|
|
11 Feb 2022 |
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
|
|
10 Feb 2022 |
IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19
|
|
10 Feb 2022 |
Akeso’s NGF monoclonal antibody (AK115) approved to initiate clinical trial in pain (including cancer pain)
|
|
10 Feb 2022 |
FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
|
|
09 Feb 2022 |
Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product
|
|
08 Feb 2022 |
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
|
|
07 Feb 2022 |
Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy
|
|
07 Feb 2022 |
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
|
|
05 Feb 2022 |
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
|
|
04 Feb 2022 |
Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders
|
|
04 Feb 2022 |
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
|
|
03 Feb 2022 |
Regio Biosciences Enters into License Agreement with AstraZeneca for Phase 2a Asset in Peripheral Artery Disease (PAD)
|
|
02 Feb 2022 |
Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)
|
|
01 Feb 2022 |
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
|
|
01 Feb 2022 |
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
|
|
01 Feb 2022 |
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
|
|
01 Feb 2022 |
Akeso doses first patient in the phase III trial of ivonescimab combined with chemotherapy in EGFR-TKI resistant EGFR mutation advanced non-squamous non-small cell lung cancer
|
|
01 Feb 2022 |
NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone
|
|
01 Feb 2022 |
Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
|
|
01 Feb 2022 |
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Bispecific Antibody Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
|
|
29 Jan 2022 |
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
|
